logo
logo

Rheavita Closes Eur 2.5 Million Series A Financing Co-Led By Novalis Biotech Acceleration And Pmv

Rheavita Closes Eur 2.5 Million Series A Financing Co-Led By Novalis Biotech Acceleration And Pmv

06/02/21, 7:06 AM
Location
https://purecatamphetamine.github.io/country-flag-icons/3x2/BE.svgghent
Money raised
€2.5 million
Round Type
series a
RheaVita, a company pioneering continuous freeze-drying technology for biopharmaceutical products, announced today that the company has closed a EUR 2.5 million Series A Financing. The round was co-led by Novalis Biotech Acceleration and Participatie Maatschappij Vlaanderen (PMV). Concurrent with the financing, Kjell Mortier from Novalis Biotech Acceleration and Stefan De Waele of PMV will join RheaVita’s Board of Directors.

Company Info

Company
Rhea Vita
Location
ghent, east flanders, belgium
Additional Info
RheaVita has developed a continuous, controlled freeze-drying technology that integrates all the traditional freeze-drying process steps into one continuous production line. By spinning the glass vials during the freezing process, a thin layer of product coats the inner lining of the vial. Following drying, the final solid freeze-dried product is obtained. Compared to the traditional freeze-drying process, RheaVita’s approach has several advantages, including very fast product and process development with limited experimental efforts, avoiding scale-up issues, reducing cycle times, lower production costs, less clean room space requirements, improving quality assurance and improved and uniform product quality and process uniformity. The design process was accompanied by the development of a digital twin, a ‘virtual reality’ version of the system to facilitate future process development and optimization, assist with maintenance and repair as well as training of operators. RheaVita was founded in 2018 as a spin-out of Ghent University. For more information, please visit www.rheavita.com.